Fifty-three patients with standard risk leukemia who underwent allogeneic peripheral blood stem cell transplantation (alloPBSCT) from their HLA-identical siblings were analyzed for engraftment, incidence and severity of GVHD, and relapse rate. Standard risk leukemia was defined as AML in first complete remission or CML in first chronic phase within the first year after diagnosis. The median age was 34.5 years (range 13-47). Stem cells were mobilized by using 10 g/kg G-CSF subcutaneously for 5 days. A median of 5.7 (2.1-21.4) × 10 6 /kg CD34 + cells was collected over a median of 2 (range 1-5) apheresis procedures. Cyclosporin A (CsA) plus short-course MTX were used for GVHD prophylaxis. Recovery to granulocytes Ͼ0.5 × 10 9 /l and platelets Ͼ20 × 10 9 /l occurred at a median of day +13 (range 8-32) and +13 (range 8-51), respectively. Day +100 transplant-related mortality was 13.2% (7/53). Acute GVHD occurred in 20 of 49 (41%) evaluable patients and only six (12.3%) of them had severe disease (grade III-IV). Chronic GVHD occurred in 30 of 42 (71.4%) evaluable patients. Relapse rate at 2 years was 7.5%. The median overall and leukemia-free survivals were 22 (4-44) and 20 (3-44) months, respectively. Estimated 4 year leukemia-free and overall survival rates were 60% and 62%, respectively. In conclusion, alloPBSCT in standard risk leukemia seems to be associated with a low relapse rate and no increased risk of acute GVHD, but there is a trend for higher incidence of cGVHD. Bone Marrow Transplantation (2000) 25, 1229-1232.
far. While faster neutrophil and platelet engraftment with shorter duration of hospitalization and lower antibiotic use have been seen compared to BMT, 8, 9 whether or not GVHD is more common and the relapse rate is different, is not yet clear. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In this report, we summarize our experience with alloPBSCT in standard risk leukemia: AML in first complete remission (CR), or CML in early first chronic phase.
Patients and methods

Patients
Fifty-three patients with standard risk leukemia underwent alloPBSCT at the İbni Sina Hospital between 1995 and 1999. Patient characteristics are shown in Table 1 . Standard risk leukemia was defined as AML in first CR (CR1) (26 patients), and CML in first chronic phase within the first year after diagnosis (27 patients). 18 
Donors
Stem cell donors were HLA-identical siblings. The median age was 30.5 (range 11-47). Twenty-nine were male and 24 were female. There were 26 donor-recipient sex mismatches. Informed consent was obtained from the donors and patients.
HLA typing
Class I and II HLA antigens were analyzed serologically and by molecular techniques (SSO-SSP), respectively. 
PBSC mobilization and collection
Recombinant human granulocyte colony-stimulating factor (rhG-CSF, Neupogen; Amgen, Roche, Istanbul, Turkey) was used for mobilization. Ten g/kg G-CSF was given daily subcutaneously for 5 days. Apheresis was performed on day 5 using a continuous flow cell separator (COBE Spectra; COBE BCT, Lakewood, CO, USA). A total of 119 leukapheresis cycles (median 2, range 1-5) were performed using peripheral veins. The target was Ͼ4 × 10 6 /kg CD34 + cells and processing twice the total blood volume of the donor. No manipulation was performed on the collected material and products were transfused immediately on the same day.
Flow cytometry
PBSC were analyzed by flow cytometry for hematopoietic progenitor cells (CD34; HPCA-2, Becton Dickinson, San Jose, CA, USA) and lymphoid sub-populations (CD3 + ) using standard procedures.
Conditioning regimen and GVHD prophylaxis
All patients were conditioned with BU 16 mg/kg p.o. and CY 120 mg/kg iv. Cyclosporin-A (CsA) (3 mg/kg/day i.v.) plus short-course MTX (15 mg/m 2 i.v. on day +1 and 10 mg/m 2 i.v. on subsequent days +3, 6 and 11) were used for GVHD prophylaxis in all patients. After day +180 CsA was tapered (25 mg every 3 weeks) if the patient had no sign of GVHD. Diagnosis and grading of acute GVHD (aGVHD) were based on standard criteria. 19 
Engraftment
None of the patients received post-transplant hematopoietic colony-stimulating factors. Engraftment was defined as the first day of a granulocyte count Ͼ0.5 × 10 9 /l and an unsupported platelet count Ͼ20 × 10 9 /l for 3 consecutive days.
Chimerism study
In order to detect chimerism, we used HLA polymorphism, sex mismatches, and ABO blood group mismatches. We used VNTR for HLA polymorphism, FISH for sex mismatches and ABO group typing for ABO mismatches. All the above analyses except ABO typing were performed on bone marrow samples on the day of discharge and on day +100.
Statistical analysis
Disease-free survival and overall survival were estimated by using the method of Kaplan and Meier. 
Results
Collection and engraftment
The median number of aphereses was 2 (1-5 Table 2 ). Granulocytes Ͼ1.0 × 10 9 /l and platelets Ͼ50 × 10 9 /l were achieved on days +15 and +14, respectively. There was no correlation between the CD34 + cell dose and hematological recovery (r = −0.162 and P = 0.29).
Chimerism study
Complete chimerism (CC) was documented in the majority of our patients. Sex chromosome-based FISH (10 of 10) and conventional cytogenetics revealed CC in five patients (no metaphases could be gained in 11 patients) of sex mismatched patients. ABO blood grouping revealed conversion of blood groups to donor type in 85.7% (18 of 21) of relevant patients. By using variable non-tandem repeats CC was shown in 81.3% (13 of 16) of the patients studied.
GVHD
GVHD profile of the patients are given in Table 3 . GVHD occurred in 20 of 49 (41.1%) evaluable patients. Grade III-IV was in six of 49 (12%) patients. Chronic GVHD was observed in 30 out of 42 (71.4%) evaluable patients. Nine Table 4 Organ involvement in chronic GVHD patients died due to GVHD (four acute, five chronic). Organ involvement in cGVHD is shown in Table 4 . Liver was the most commonly involved organ. Deterioration of liver function was detected in almost all the patients while tapering CsA after day +100. Median time to cGVHD was 4 (4-19) months. CsA administration could not be discontinued as planned in these patients because of cGVHD. Median time to CsA cessation was 16 (7-25) months.
Outcome
Median follow-up was 22 (11-44) months. Major causes of death are shown in Table 5 . Day +100 transplant-related mortality was 13.2% (seven of 53). Thirty-five patients are still alive, 34 disease-free. Relapse occurred in five patients (three AML, two CML). One patient with CML relapsed with blast crisis 16 months post transplant while suffering from extensive cGVHD. Another patient in second chronic phase is receiving DLIs. One AML patient relapsing 4 months after transplantation achieved CR2 with standard induction therapy. Later on, donor leukocytes were infused from her original donor and complete chimerism was documented after DLI. This patient is still alive in CR2 17 months after DLI. The second AML patient refused further treatment and the third one died during induction therapy. Kaplan-Meier curves of overall and leukemia-free survival of the patients are shown in Figures 1 and 2 . The estimated 5 year leukemia free-and overall survival rates are 60% and 62%, respectively.
Discussion
We have evaluated the kinetics of engraftment, the incidence of acute and chronic GVHD and relapse rate in a considerable number of standard risk leukemia patients, who were treated homogenously. In the current study, median granulocyte and platelet engraftments were on day +13 and +13 respectively. In our historical 40 alloBMT patients, some of whom were high risk patients, engraftment of granulocytes and platelets occurred on days +19 (12-50) and +27 (13-70), respectively. 11 Clearly, faster hematological recovery is seen in standard risk leukemia patients after alloPBSCT. The overall incidence of aGVHD (41%) and of grade III-IV aGVHD (12%) were comparable to those reported in the literature. Whether the incidence of cGVHD increased in patients undergoing alloPBSCT is still controversial. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] There appears to be a trend towards a higher incidence of cGVHD. 18 Our previous retrospective comparative study (containing standard as well as high risk patients) showed an increased cGVHD compared to bone marrow (24.1% vs 78.1%). 11 The current study, comprising only standard risk patients, revealed that 30 out of 42 patients (71.4%) developed cGVHD. In AML patients treated with alloPBSCT, we have seen cGVHD in 70% of the patients. 21 Although randomized trials will resolve this issue, it is our opinion that cGVHD is more common in alloPBSCT compared to bone marrow transplantation.
The relapse rate in this study was low (five of 42). Two reasonable explanations may account for this result. The first is that this study included standard risk leukemia patients. They were under 35 years old and were transplanted during the early phases of their diseases. However, even in these circumstances, according to EBMT and IBMTR data, the 2-year relapse rates for AML and CML patients are 15-20% after allogeneic bone marrow transplantation. The second explanation is that a graft-versusleukemia effect and/or cGVHD due to increased T cell doses may be responsible. We do not know whether other transplant-related variables specific for alloPBSCT, such as high dendritic cell content of the harvest material, may have contributed to this low relapse rate.
In conclusion, in standard risk leukemia patients, alloPBSCT is an alternative to allogeneic bone marrow transplantation because of the ease of collection and rapid hematological recovery. In our study, alloPBSCT was not associated with increased risk of acute GVHD, but there was a suggestion of increased cGVHD. In addition, it was also associated with an unusually low relapse rate.
